Session: SUN 459-496-Thyroid Neoplasia & Case Reports
Poster Board SUN-479
tumors, but rarely show a more aggressive course.
Objective: We aimed to figure out the clinicopathological features of PTMC and to identify determinants of recurrence in the disease course.
Design: Data from the medical records of patients with PTMC followed in our instutition over a 25 year period were retrospectively analyzed.
Results: Overall, 368 patients (82 % female) with a mean age at diagnosis of 46±12years and a follow-up duration of 5.2±4.5 (0-24) years were included. Hyperthyrodism was noted in 27% of patients at initial presentation whereas Hashimoto’s thyroiditis was present in 22 %. The mean tumor diameter was 5.4± 2.8 milimeters (mm). Multifocal disease was present in 46% (unilateral 21%, bilateral 25%). Classical and follicular variants were the most common subtypes (69 and 25%, respectively). The prevalance of capsular invasion, lymphovascular invasion, lymph node metastasis and distant metastasis were 4.6, 6.3, 4.9 and 0.8% respectively. 42% of the patients recieved radioactive iodine ablation therapy. Recurrence of the disease were present in 10 patients (2,7%). Capsular invasion, lymph node metastasis, and recurrence were significantly higher in the patients with multifocal disease and in those with a tumor diameter greater than 5 milimeters. In the logistic regression analysis, multifocality [p<0.05, Odds ratio:6.447 (CI:1.082-38.428)] and tumor diameter [p<0.05, Odds ratio:1.329 (CI:1.007-1.755)] were found to be the major determinants of disease recurrence.
Conclusions: Multifocality and tumor diameter appears to have predictive value for disease recurrence in PTMC. Despite the favorable prognosis of the disease, we recommend careful lifelong follow-up of the patients, especially those with multifocal disease and larger tumor diameter.
Disclosure: AC: Consultant, Novartis Pharmaceuticals, Speaker, Novartis Pharmaceuticals, Speaker, Sanofi, Consultant, Sanofi, Speaker, Astra Zeneca, Speaker, Bristol-Myers Squibb, Consultant, Novo Nordisk, Speaker, Novo Nordisk, Speaker, Eli Lilly & Company. Nothing to Disclose: AG, TD, MY, OO, SAY, FB, SE, MG, AOI, MAK, TC
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters